


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : B01L 3/02, G01N 1/38, 21/82	A1	(11) International Publication Number: WO 99/47261 (43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: PCT/CA99/00236 (22) International Filing Date: 19 March 1999 (19.03.99) (30) Priority Data: 60/078,780 19 March 1998 (19.03.98) US (71) Applicant (for all designated States except US): CME TELEMETRIX INC. [CA/CA]; 560 Parkside Drive, Waterloo, Ontario N2L 5Z4 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): SAMSOONDAR, James [CA/CA]; 40 Hilborn Avenue, Cambridge, Ontario N1T 1M7 (CA). (74) Agent: BERESKIN & PARR; 40 King Street West, 40th floor, Toronto, Ontario M5H 3Y2 (CA).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD AND APPARATUS FOR MEASURING PROTEINS (57) Abstract <p>An apparatus and method for performing immunoturbidimetric measurements of plasma proteins on an apparatus used for measuring plasma and serum interferents are described. Immunoturbidimetric measurements are made on a sample in a disposable dispensing tip which acts as cuvette and reaction chamber. These features allow tests which are not available on general chemistry analyzers, to become available, and at the same time the apparatus can provide a screening system for serum and plasma interferents.</p> 		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: METHOD AND APPARATUS FOR MEASURING PROTEINS**FIELD OF INVENTION**

This invention relates to immunoturbidimetry and spectrophotometric analysis of plasma for proteins.

5 BACKGROUND OF INVENTION

Clinical laboratory tests are routinely performed on serum or plasma of whole blood. In a routine assay, red blood cells are separated from plasma by centrifugation, or red blood cells and various plasma proteins are separated from serum by clotting prior to centrifugation.

10 Haemoglobin (Hb), bilirubin (BR), biliverdin (BV), and light-scattering substances like lipid particles are typical substances which will interfere with and affect spectrophotometric and other blood analytical measurements. Such substances are referred to generally, and in this specification as interferents. Elevated BR and BV referred to as bilirubinemia and biliverdinemia respectively can be due to disease states,
15 increased lipid particles in the blood also known as lipemia, can be due to disease states and dietary conditions; elevated Hb in the blood known as haemoglobinemia can be due to disease states and as a result of sample handling.

Many tests conducted on plasma or serum samples employ a series of reactions which terminate after the generation of chromophores which facilitate detection by
20 spectrophotometric measurements at one or two wavelengths. Measurement of the quantity of interferents in a sample prior to conducting such tests is important in providing meaningful and accurate test results. In fact if a sample is sufficiently contaminated with interferents, tests are normally not conducted as the results will not be reliable.

Current methods used for detecting haemoglobinemia, bilirubinemia and lipemia
25 or turbidity utilize visual inspection of the sample with or without comparison to a color chart. Visual inspection is sometimes employed on a retrospective basis where there is a disagreement between test results and clinical status of the patient in order to help explain such discrepancies.

Pre-test screening of samples by visual inspection is semi-quantitative at best, and
30 highly subjective and may not provide sufficient quality assurance as required for some tests. Furthermore, visual inspection of samples is a time consuming, rate limiting process. Consequently, state-of-the-art blood analyzers in fully and semi automated laboratories do not employ visual inspection of samples.

Other methods used to assess the amount of contamination of a sample, i.e.,
35 sample integrity, employ direct spectrophotometric measurement of a diluted sample in a special cuvette. In order to obtain a measurement of the sample of the plasma or serum, sample tubes must be uncapped, a portion of the sample taken and diluted prior to

measurement. Both of these steps are time consuming and require disposable cuvettes.

An apparatus used for measuring sample integrity can also be used to measure plasma proteins, e.g., Immunoglobulin A (IgA), β 2-microglobulin and C-reactive protein (CRP). To do so, an antibody reagent is required for each protein, and a 37°C incubation chamber. This method of analysis is called immunoturbidimetry because the specific antibody reagent forms immunocomplexes with the corresponding protein, when present in the sample. The immunocomplexes scatter light in various directions depending on the size distribution of the immunocomplexes or particles; turbidity in a sample is a result of scattered light and the absorbance increase is inversely proportional to wavelength. It must be understood that the use of the term absorbance includes "true absorbance" and the effect of light loss by any other means; the detector in the spectrometer measures the light transmitted through the sample, and absorbance is calculated as the negative log of transmittance. Therefore, any light which does not reach the detector, e.g., due to scattering caused by turbidity, will be interpreted as absorbed light.

For proteins in low concentrations, e.g., in the order of mg/L, the turbidity created by immunocomplexes is very small and are usually measured in one of two ways: 1) Measurement of light scattered in the forward direction on an instrument called a nephelometer, which is like a spectrophotometer that measures light propagated at an acute angle to the incident light. Such a method would require a separate instrument which would increase the cost per test; 2) Measurement of "absorbance" at 340nm by a spectrophotometer. In the prior art which uses absorbance measurements, the absorbance at 340nm at zero time is subtracted from the absorbance at 340nm after incubation at approximately 37°C for approximately five minutes, in order to remove the effect of sample interferents. This approach cannot be used for the near infrared (NIR) and adjacent visible wavelengths where the light-scattering caused by the immunocomplexes is very small.

SUMMARY OF THE INVENTION

It is desirable to use an apparatus designed for measuring plasma and serum interferents to perform immunoturbidimetric measurements. This feature allows tests which are not available on general chemistry analyzers, to become available, and at the same time the apparatus can provide a screening system for serum and plasma interferents.

The present invention uses a novel wavelength range and method to subtract endogenous sample turbidity and the effect of other interferents. The present invention uses a disposable dispensing tip in a novel way both as a reaction and incubation chamber, as well as a cuvette. The use of a disposable dispensing tip as a reaction chamber and cuvette allows this invention to be integrated into a chemistry analyzer, or built as a stand-alone instrument for measuring serum and plasma interferents as well as plasma

proteins. This invention is particularly relevant to chemistry analyzers which do not already possess similar optical hardware as described for this invention, which could facilitate the measurement of serum and plasma interferents, and plasma proteins. By integrating such optical capabilities in the chemistry analyzer, the current test menu can
 5 be expanded by offering immunoturbidimetric measurements.

Accordingly, the present invention provides an apparatus for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry, said apparatus comprising:

- a blood analyzer;
- 10 a disposable dispensing tip;
- means for sealing a first end of the disposable dispensing tip;
- a second tip capable of being inserted into an open second end of the disposable dispensing tip for adding one or more reagents to the disposable dispensing tip;
- a heated cavity for receiving the sample in the disposable dispensing tip of the analyzer;
- 15 means for transferring the disposable dispensing tip into and out of the heated cavity;
- a radiation source for emitting a beam of radiation;
- means for directing the radiation onto the sample in the disposable dispensing tip;
- a sensor responsive to receipt of the radiation; and
- 20 means for correlating said concentration of the one or more proteins in the sample to a sensor response from the sample. Preferably the means for sealing is a vice and the radiation source means, means for directing said radiation onto said sample, and sensor are contained in a spectrophotometer. More preferably the beam of radiation is near infrared and adjacent visible region light and has wavelengths from about 475nm to about
 25 910nm.

An apparatus of the invention for the correlation referred to above incorporates calibration algorithms in respect of IgA, β 2-microglobulin and C-reactive protein (CRP) respectively which are:

- a. $\text{mg/L IgA} = -a(X_{\text{nm}}) + b(Y_{\text{nm}}) - c$
- 30 where a, b and c are coefficients of the first derivative of absorbances at the wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first derivative of the absorbance at wavelength Y; preferably $a = 3327100-3327120$, $b = 484250-484290$ and $c = 70-85$, more preferably $a = 3327114.33$, $b = 484270.80$ and $c = 77.3$; where X is about 780-800 nm, and Y is about 820-830 nm, preferably X is about 789 nm and Y
 35 is about 825 nm

- b. $\text{mg/L } \beta 2\text{-microglobulin} = a(X_{\text{nm}}) + b(Y_{\text{nm}}) + c$
- where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first

derivative of the absorbance at wavelength Y; preferably $a = -33640-33660$, $b = 36550-36560$ and $c = 2-3$, more preferably $a = -33648.79$, $b = 36556.81$ and $c = 2.3$; where X is about 545-550 nm and Y is about 825-835 nm, preferably X is about 548 nm and Y is about 829 nm;

$$c. \quad \text{mg/L CRP} = a(X_{nm}) + b(Y_{nm}) + c$$

- 5 where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first derivative of the absorbance at wavelength Y; preferably $a = (-1813675)-(-1813685)$, $b = 1808670-1808680$ and $c = 9.5-10$, more preferably $a = -1813682.71$, $b = 1808677.58$ and $c = 9.8$; where X is about 655-665 nm and Y is about 675-685 nm, preferably X is about 661 nm and Y is about 679 nm.

In another aspect the invention, there is provided a method for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry in a blood analyzer, the method comprising:

- 15 filling a disposable dispensing tip with the sample;
sealing a first end of the tip with means for sealing;
adding a reagent to an open second end of the disposable dispensing tip with a second tip capable of being inserted into the open end;
placing the disposable dispensing tip into a heated cavity;
radiating the sample in the disposable dispensing tip with a source which emits a
20 beam of radiation;
sensing the radiation having passed through the sample;
correlating the concentration of said one or more proteins in said sample to the sensor response from the sample. The disposable dispensing tip which contains the reagent or reagents and sample may be removed from the heated cavity prior to being
25 subjected to radiation. The preferred means for sealing is a vice. The method also contemplates that the beam of radiation is near infrared and adjacent visible region light, preferably the near infrared and adjacent visible region light has wavelengths from about 475nm to about 910nm.

- Concerning this method the correlation referred to above incorporates calibration
30 algorithms in respect of IgA, $\beta 2$ -microglobulin and C-reactive protein (CRP) respectively which are:

$$a. \quad \text{mg/L IgA} = -a(X_{nm}) + b(Y_{nm}) - c$$

- where a, b and c are coefficients of the first derivative of absorbances at the wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first derivative of the absorbance at wavelength Y; preferably $a = 3327100-3327120$, $b = 484250-484290$ and $c = 70-85$, more preferably $a = 3327114.33$, $b = 484270.80$ and $c = 77.3$; where X is about 780-800 nm, and Y is about 820-830 nm, preferably X is about 789 nm and Y is about 825 nm

$$b. \quad \text{mg/L } \beta 2\text{-microglobulin} = a(X_{nm}) + b(Y_{nm}) + c$$

where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first derivative of the absorbance at wavelength Y; preferably $a = -33640-33660$, $b = 36550-36560$ and $c = 2-3$, more preferably $a = -33648.79$, $b = 36556.81$ and $c = 2.3$; where X is about 545-550 nm and Y is about 825-835 nm, preferably X is about 548 nm and Y is about 829 nm;

$$c. \quad \text{mg/L CRP} = a(X_{nm}) + b(Y_{nm}) + c$$

where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X_{nm}) is the first derivative of the absorbance at wavelength X; (Y_{nm}) is the first derivative of the absorbance at wavelength Y; preferably $a = (-1813675)-(-1813685)$, $b = 1808670-1808680$ and $c = 9.5-10$, more preferably $a = -1813682.71$, $b = 1808677.58$ and $c = 9.8$; where X is about 655-665 nm and Y is about 675-685 nm, preferably X is about 661 nm and Y is about 679 nm.

The present invention also provides a method for determining the concentration of plasma protein IgA, $\beta 2$ -microglobulin or C-reactive protein in a plasma sample by immunoturbidimetry in a blood analyzer, said method comprising:

aspirating a small volume of plasma into a disposable dispensing tip;

further aspirating the small sample in the sample tip to pull the sample away from the lower end of the tip;

sealing the lower end of the tip with means for sealing the tip without trapping air below the sample in the tip;

adding an antibody reagent to the disposable dispensing tip with a second dispensing tip, the second tip is capable of being inserted into the open end of the disposable dispensing tip;

heating the disposable dispensing tip in a heating cavity;

radiating the sample in a disposable dispensing tip in a spectrophotometer; and

correlating the concentration of the IgA, $\beta 2$ -microglobulin or C-reactive protein in the sample to a sensor response from the sample. Preferably

the temperature of the heating cavity is 37°C and the tip is maintained in a heating cavity for 2 minutes. More preferably, the plasma sample is 5 μL . In a preferred embodiment the antibody reagent is about 60 μL of antibody selected from the group consisting of: antibody reactive to IgA; antibody reactive to $\beta 2$ microglobulin; and antibody reactive to C reactive protein.

DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective view of a system incorporating an apparatus of the present invention for analyzing sample integrity and measuring a variety of proteins;

Figure 2 is a schematic representation of elements of the apparatus of Figure 1;

Figure 3 is a perspective view of two disposable dispensing tips and jaws of a small vice used to squeeze the lower end of the tip, for the purpose of sealing;

Figure 4 is a graphic representation of the absorbance spectra of variable amounts of IgA, zero time after incubation with antibodies against IgA, at 37°C, in the dispensing tip of an analyzer. The concentration of IgA is shown in the figure;

Figure 5 is a graphic representation of the absorbance spectra of variable amounts of IgA, 2 minutes after incubation with antibodies against IgA, at 37°C, in the dispensing tips of an analyzer. The concentration of IgA is shown in the figure;

Figure 6 is a graphic representation of a linear regression fit for data used for the development of an IgA calibration algorithm for samples in dispensing tips of an analyzer, with IgA in units of milligrams per litre on the abscissa and ordinant axes;

Figure 7 is a graphic representation of a linear regression fit for data in respect of predicted IgA concentration for samples not used in the calibration process, for samples in dispensing tips of an analyzer, with IgA in units of milligrams per litre on the abscissa and ordinant axes;

Figure 8 is a graphic representation of a linear regression fit for data used for the development of a β 2-microglobulin calibration algorithm for samples in dispensing tips of an analyzer, with β 2-microglobulin in units of milligrams per litre on the abscissa and ordinant axes;

Figure 9 is a graphic representation of a linear regression fit for data used for the development of a C-reactive protein calibration algorithm for samples in dispensing tips of an analyzer, with C-reactive protein in units of milligrams per litre on the abscissa and ordinant axes;

Figure 10 is a graphical representation of the percent error in IgA prediction caused by endogenous turbidity created by intralipid, with and without subtraction of the 1st derivative of the absorbance at zero time.

DESCRIPTION OF THE INVENTION

As discussed above, the present invention provides apparatus and a method for performing immunoturbidimetric measurements on an apparatus used for measuring plasma and serum interferents. This feature allows tests which are not available on general chemistry analyzers, to become available, and at the same time the apparatus can provide a screening system for serum and plasma interferents. The apparatus for measuring serum and plasma interferents comprises a housing for receiving a sample; a radiation source; a sensor; a means for optically connecting the radiation source with the sensor along a sample path through the housing and along a reference path which bypasses the sample; a means for selectively passing a beam from the sample path and from the reference path to the sensor; and a means for correlating a sensor response, from the sample path relative to a sensor response from the reference path, to a quantity of a

known substance in said sample. The sample housing can be an integral part of the conveyor system as shown in Figure 1, or the housing can have a cavity for receiving a sample and a lid for selectively opening and closing the cavity, also shown in Figure 1. A cover may not be necessary in an automated system, where the dispenser stem, when
5 inserted into the dispensing tip, can provide sufficient light shielding, and further because of the strategic location of the shutters, the subtraction of dark current from both the sample and the reference light measurements, can effectively eliminate the effect of room light. The radiation source is for emitting a beam of radiation, and the sensor is responsive to receipt of radiation. In order to perform immunoturbidimetry using an
10 existing apparatus, a means for sealing the lower end of the dispensing tip as required. In a preferred embodiment the means for sealing is a small vice. A preferred example of a dispensing tip is the disposable tip used by the Vitros™ analyzer manufactured by Johnson and Johnson.

The apparatus further comprises a quartz-tungsten-halogen lamp capable of
15 emitting a near infrared, and adjacent visible region light beam having wavelengths from 475nm to 910nm and a bifurcated fibre-optic cable for splitting the light beam from the quartz-tungsten-halogen lamp into a sample path beam for travel along a sample path and a reference path beam for travel along a reference path. This apparatus further comprises a shutter for selectively blocking the sample path light beam which travels
20 along the sample path and the reference path light beam which travels along the reference path, as well as optical fibre bundles for transmitting the sample path light beam through a sample enclosed in the housing, and optical fibre bundles for transmitting the sample path light beam from the sample to a second bifurcated fibre-optic cable, where the beam from the sample path and the beam from the reference path converge
25 into a single fibre-optic cable. It is understood that any means for excluding from the sample, light other than that from the radiation source of the apparatus, is within the scope of this invention. Also, if dark current, i.e., sensor response when sensor is not exposed to the instrument light, is subtracted from both the reference and sample measurements, the room light impinging on the detector can be effectively subtracted
30 without affecting the instrument performance significantly.

Preferably, the bottom end of the dispensing tip is sealed by flattening between the jaws of a small vice, after a sample is aspirated into said tip. Preferably the dispensing tip is disposable and more preferably the tip of an analyzer is used as a reaction and incubation chamber after the tip is sealed with the sample inside, and the
35 same sealed dispensing tip is used as a cuvette.

Analytes, such as proteins, preferably Immunoglobulin A (IgA), β 2-microglobulin and C-reactive protein (CRP), can be measured on the apparatus through the use of reagents, eg. antibodies, by the process of immunoturbidimetry. Each plasma

protein requires a specific antibody, and the specificity of each test can be increased by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after approximately 2 minutes at 37°C, at single or multiple wavelengths. It will be understood that optimum incubation time and temperature may vary for different plasma proteins.

Only 5µL of sample and 60µL of antibody reagent is required. It will be understood that optimum sample and reagent volumes may vary for different proteins.

In another aspect of the invention, the same dispensing tip used to aspirate 5µL of sample is sealed at the lower end by increasing the vacuum on the tip by an equivalent of 4µL. It will be understood that deviations from this volume are within the scope of this invention, particularly when other disposable tips are used. The extra vacuum equivalent to an aspiration of 4µL, is sufficient to pull the fluid away from the lower end of the tip which is within the grasp of the jaws of a small vice without trapping air below the 5µL of sample, and without trapping sample below or within the seal.

According to a preferred embodiment, the jaws are slightly nonparallel as shown in Figure 3, and will therefore force upwards any residual fluid which is in the grasp of the jaws. This aspect of the invention assists in reducing any loss of any part of the sample.

In practising the invention, an antibody reagent is mixed with the sample by injecting 60µL of antibody reagent into 5µL of a sample. Preferably, 60µL of antibody reagent is in a narrow pipette tip, e.g., as shown as 4 in Figure 3, which can reach the bottom of the sealed tip, allowing enough space to facilitate proper dispensing of the antibody reagent. More preferably, narrow tips such as shown as 4 in Figure 3 are 960 Envirotips® manufactured by Eppendorf, but any similar tip may be used. It is desirable that the ratio of antibody reagent volume to sample volume facilitates adequate mixing of sample and reagent. In carrying out the invention it is preferable if the ejection of the antibody reagent is such that only the fluid is ejected and no air is injected into the reaction chamber.

Zero-time absorbance measurement is triggered after antibody reagent is dispensed into a sealed tip of the invention, and the zero-time measurement is performed with the dispensing stem attached to the tip.

According to one embodiment of the invention, the tip holder has a sliding lid which closes after antibody reagent is dispensed.

In another aspect of the invention, because of the location of the shutters in the lamp assembly the subtraction of dark current from both the sample and the reference light measurements, can effectively eliminate the effect of room light. Preferably the sample chamber is shielded from light but is not required to be completely light-tight; a cover may not be necessary in an automated system, where the dispenser stem, when

inserted into the dispensing tip, can provide sufficient light shielding, even when dark current is not subtracted.

In another embodiment of the invention, the spectrometer can be run in single-beam mode.

5 In another aspect of an alternative embodiment of the invention, zero-time measurement is used as the reference scan when the spectrometer is run in the single-beam mode. Preferably the rate of change of the first derivative of absorbance is monitored during the first 15 seconds, to forecast if a high-dose hook effect will occur.

10 Immunoturbidimetric measurements are performed using multiple wavelengths in the visible and NIR electromagnetic radiation.

A method of the invention provides for measuring the concentration of a series of proteins in a sample by recording the absorbance spectrum of the sample before and after incubation with antibodies specific to each protein. Preferably the effect of interferents in a sample can be minimized by virtue of the wavelength range used, i.e., NIR and adjacent visible radiation. More preferably the remaining effect of interferents can be substantially removed by subtracting the first derivative of absorbance at zero time from the first derivative of absorbance after a two-minute incubation at 37°C. It will be understood that other times and incubation temperatures can be used.

20 The effect of small air bubbles on absorbance is minimized by using the first derivative of absorbance. It will be understood that any higher order of derivative of absorbance may also be used, eg., second derivative of absorbance.

A system incorporating the apparatus of the present invention is generally illustrated in Figure 1. The apparatus 10 generally comprises a spectrometer 14 optically coupled to, or communicating with a sample held on the conveyor 94 through fibre optic bundles 44 and 46, installed in a cover 92, or a sample holder 98 with a cover 100. Apparatus 10 is mounted or installed adjacent to an automated conveyor 94 which carries a plurality of sample tubes, e.g. 86 and 88. Because samples are presented in variable tube sizes, there may be a gap between the walls of the tube and the ends of fibres 44 and 46, focusing lenses 96 are attached to the ends of the fibres. Sample holder 98 is designed for a disposable dispensing tip. Cover 92 acts as a light shield and also provides a restraint for the fibres 44 and 46, against any movement.

35 Cover 100 in Figure 1 also acts as a light shield for the apparatus. The dispensing stem of an analyzer and the tip holder can act as a light shield, with the tip holder designed deep enough to accommodate the stem of the analyzer dispenser. Neither the tip holder and cover 100, nor cover 92 are intended to provide a light-tight sample chamber. Sample presentation on a conveyor line 94 in Figure 1 is only relevant to the analysis of sample integrity functionality of the spectrometer. For the present invention, a sample is presented to the optical apparatus in a tip holder 98 in Figure 1.

For the measurement of proteins by immunoturbidimetry, a separate sample holder such as that illustrated (98) is required, and is imbedded in a heated block. In a preferred embodiment, 5 μ L of plasma is aspirated in a dispensing tip, as shown as 1 in Figure 3. Extra vacuum, equivalent to an aspiration of 4 μ L is applied to the sample to pull the fluid away from the lower end of the tip which is within the grasp of the jaws as shown in Figure 3. Different volumes can be used, it being understood that the objective is to have the sample removed far enough from the tip and to allow for sealing. The extra vacuum must be sufficient to pull the fluid away from the lower end of the tip, without trapping air below the 5 μ L of sample. The same dispensing tip used to aspirate 5 μ L of sample is sealed after the sample is aspirated into said tip. The end of the dispensing tip is sealed underneath the 5 μ L of sample by squeezing between the jaws of a small vice, shown as 5 in Figure 3. The sealed tip with a flattened lower end is shown as 2 in Figure 3. It will be understood that although Figure 3 shows a Vitros™ tip as 1 and 2, other disposable tips can be used and deviations from 4 μ L are within the scope of this invention, particularly when other disposable tips are used. The jaws 5 in Figure 3 are slightly nonparallel, and will therefore force upwards, any residual fluid which is in the grasp of the jaws. This aspect of the invention precludes loss of any part or the 5 μ L of the sample.

In this invention, analytes are measured on the apparatus through the use of reagents by the process of immunoturbidimetry. Each protein requires a specific antibody, and the specificity of each test can be increased by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after approximately 2 minutes at 37°C, at a single or multiple wavelengths. It will be understood that optimum incubation time and temperature could vary for different proteins.

60 μ L of antibody reagent is aspirated from a bottle into a narrow pipette tip shown as 4 in Figure 3. In a preferred embodiment, narrow tips shown as 4 in Figure 3 are 960 Envirotips® manufactured by Eppendorf, but any similar tip which can reach the bottom of the sealed tip may be used. The Eppendorf tip or its equivalent must be allowed to reach the bottom of the Vitros tip or its equivalent, with just enough space between the ejection port and the 5 μ L of sample, to facilitate proper dispensing of the antibody reagent. The antibody reagent is mixed with the sample by injecting the 60 μ L of antibody reagent into the 5 μ L of sample. Little or no air should be injected into the sample. This can be accomplished by injecting the 60 μ L or less of the antibody reagent, as long as the volume is dispensed in a precise manner. It will be understood that further mixing can be achieved by reaspirating and redispensing the reaction mixture.

The disposable dispensing tip of an analyzer is used as a reaction and incubation chamber after the tip is sealed with the sample inside; it is also used as a cuvette. Although Figure 1 only shows one tip holder 98, a preferred embodiment contains two tip

holders 98; one used for measurement of interferents and the other for protein measurement. It will be understood that one tip holder can be used for both applications, and the single tip holder is heated for the benefit of the protein measurement, without affecting the interferent measurements, since the dwell time for the interferent measurement is only one second. When two separate tip holders are installed, they are connected through a bifurcated optical fibre, to the sample optical fibre 44 in Figure 1. Two new shutters must be installed external to the lamp assembly 20 in Figures 1 and 2. The new shutters allow light to be directed only to the tip holder which is functional.

Zero-time absorbance measurement is triggered after the antibody reagent is dispensed, with the dispensing stem attached to the tip. In another embodiment of the invention, the tip holder has a sliding lid which closes after the antibody reagent is dispensed, and after the dispensing stem releases the tip. The effect of interferents can be substantially removed by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after a two-minute incubation at 37°C. It will be understood that other times and incubation temperatures can be used. In this design, the sample holder functions as both the incubator and the optical read station. It will be understood that the incubation can occur in a separate chamber, where the incubated sample can be aspirated into a disposable dispensing tip, which is subsequently placed in the tip holder 98 as shown in Figure 1. If a separate incubation chamber is used, the same read station or tip holder 98, as shown in Figure 1, can be used for both interferent and protein measurements. If a combined incubator-read station is used, then a separate tip holder is required for measuring interferents, and a separate set of optical fibres and shutters are required to supply and receive radiation to and from the "incubator-read station". If it is desired to have the dispensing stem remain with the dispensing tip, a second dispensing stem, can be added to the apparatus.

Sample fibres 44 and 46 direct radiation from a light source to and from the sample respectively, and allow the bulk of the instrumentation to be placed remotely from the samples. Multiple optical fibres 46 and 48 are the strands of a bifurcated optical fibre which collect radiation alternately from the sample 44 and reference optical fibre 66, and combines into one multiple optical fibre 54 which communicates with a spectrometer 14. Reference fibre 66 is joined to a strand 48 of the bifurcated fibre by a coupling 52. The coupling 52 can be chosen to provide sufficient attenuation of the reference beam, where the detector is optimally integrated over a short period of time. Fibre 66 is a single fibre and fibre 44 can be a single or multiple fibres, depending on the light throughput required.

Referring to Figure 1, the apparatus 10 includes a spectrometer 14, a central processing unit 16, a power supply 18, a lamp assembly module 20 and a sample holder 92 and 94, or 98.

Referring to Figure 2, the lamp assembly module 20 employs a light source 62. Preferably the light source is a 20-watt quartz-tungsten-halogen lamp, but other wattage lamps can be employed. The input power supply is alternating current, but the output to the light source is a stabilized direct current. Attached to the lamp is a photodiode 80,
5 which monitors lamp output. Spectral output from light source 62 is a broad band covering visible and NIR regions. Although the NIR region of the electromagnetic spectrum is generally considered to be the interval extending from 650nm to 2700nm, the nominal wavelength range of the preferred embodiment is from 475nm to 910nm, which is referred to as the "near infrared and adjacent visible region". A beam of radiation from the light
10 source 62 is directed through a band-pass filter 64 and a shaping filter 69 in the spectrometer 14. The band-pass filter is required to reduce unwanted radiation outside of 475-910nm. The shaping filter 69 is required to "flatten" the detection system's optical response. The beam of radiation from filter 64 is transmitted through a bifurcated optical multi-fibre bundle 60 to provide sample and reference beams. Bifurcated bundle 60
15 provides random sampling of lamp radiation to supply the sample and reference beams via two arms of 60, 80 and 82 respectively. In a preferred embodiment, a balanced emerging radiation is provided to the photo diode array (PDA) detector 78, from both the sample and reference paths, where the radiation through 80 and 82 are 99% and 1% respectively. With shutter 58 closed and shutter 56 open, radiation is channeled through
20 optical fibre 44 to the sample, and the radiation transmitted through the sample in multiple-labeled tube or plastic dispensing tip and is received by fibre 46, which returns collected radiation to the spectrometer 14.

The sample and reference beams enter arms 46 and 48 respectively of a bifurcated optical multi-fibre bundle which combine in fibre 54 and are focused alternately onto a
25 slit 70, by a focusing lens 68 and a shaping filter 69. Emerging radiation is collimated by lens 72 before the beam is directed to grating 74 which is a dispersing element which separates out component wavelengths in a preferred embodiment dichromated gelatin is used as the grating material. Component wavelengths are focused by a lens 76, onto the PDA 78. Each element or pixel of the PDA is set to receive and collect a predetermined
30 wavelength. In a preferred embodiment the PDA comprises 256 pixels. The pixels are rectangular in shape to optimize the amount of optical radiation detected.

Spectrometer 14 is preferably a "dual-beam-in-time" spectrometer with fixed integration time for the reference beam and a choice of integration for the sample beam. Because the sample is only shielded from light, but is not in a light-tight holder, sample
35 and reference dark scans can be subtracted from sample and reference light scans respectively; sample and reference dark scans are performed at the same integration times used for the respective light scans. In a preferred embodiment, the reference scan is performed at 13 milliseconds, and the sample scan is performed in 20 milliseconds; the

maximum ADC value obtained at 20 milliseconds for a particular sample, is used to determine a new integration time up to 2600 milliseconds, such that saturation of the detector at any pixel does not occur. The maximum time allowed for any sample depends on the required speed of sample screening. Also, multiple scans can be averaged to
5 minimize noise, but for interferent and protein measurements, the number of scans averaged must not require more than 1 second.

When in use, each pixel or wavelength portion is measured approximately simultaneously during a particular scan. Optical radiation falling on each sensor element is integrated for a specified time and individual pixels or wavelengths are samples
10 sequentially by a 16 bit analog-to-digital convertor or ADC.

Although the present embodiment details use of a PDA, any alternative means which achieves the same result is within the scope of the present invention. For example a filter-wheel system may be used. In carrying out measurements each analyte uses from one to three wavelengths or pixels. Given that the first derivative of absorbance with
15 respect to measurements with the PDA is the difference between the absorbance at two adjacent pixels, the first derivative of absorbance at one wavelength with a filter-wheel system will require absorbances measured with two different narrow band-pass filters. It will be readily understood by those skilled in the art that the filters do not need to be assembled on a rotating wheel, but that any structure which achieves the result of a
20 narrow band-pass filtration of absorbed radiation is within the scope of the present invention.

The PDA integrates the optical radiation over a specified time and converts the optical signal to a time multiplexed analog electronic signal called scan where absorbance is calculated as:

$$\text{Absorbance} = \log (\text{Reference}_i / \text{Sample measurement}_i) + \log (\text{ITM} / \text{ITR})$$

where Reference_i = reference pixel i readings;

$\text{Sample measurement}_i$ = sample measurement pixel i reading;

ITM = Integration time measurements;

30 ITR - integration time reference;

and

i = the particular pixel in the PDA.

In respect of these calculations, absorbance can also equal $\log (\text{Reference} - \text{reference dark measurement}) / (\text{sample measurement} - \text{sample dark measurement}) + \log (\text{ITM} / \text{ITR})$

Depending upon the amount of light shielding provided by the apparatus and the criticality of timing, the measurement of a reference dark and sample dark values may or may not be undertaken. The electronic signal is proportional to the time that the sensor integrates the optical signal. The electronic signal is amplified by analog electronic amplifiers and converted to a digital signal by an analog-to-digital converter or ADC. The digital information from the converter is interpreted for data analysis by a microprocessor which is in turn connected via an RS232 connector to a computer 84. The results of the data analysis can be shown on an output device such as a display and on a printer.

The first part of the process for generating a calibration curve is to store spectral data for the calibration set. The calibration algorithm for each protein must be installed in a microprocessor so that when an unknown sample is tested for a particular protein the result is quickly produced in order to calculate the quantity of any protein present, any one of several different methods, all of which are within the scope of this invention, may be used.

A preferred method is to calculate the first derivative of certain portions of the spectra in respect of the particular protein being measured. It is also possible to calculate the second, or third derivatives, and such calculations are within the scope of this invention. However, each step of taking differences to calculate those derivatives is more time consuming and introduces more noise.

In practice, an optimal combination of first derivatives of at least two portions of a spectrum generated from a scan for a particular protein are used to calculate protein concentration. The precise approach used depends on the protein being measured.

EXAMPLES

With respect to generating a calibration curve for IgA, 5 μ L of each calibrator was aspirated in a Vitros dispensing tip using an Eppendorf pipette. The pipette setting was changed from 5 μ L to 9 μ L; this extra vacuum allowed the sample to be drawn away from the end of the tip which is within the grasp of the vice shown in Figure 3. In order to prevent the fluid from leaking out, the bottom end of the dispensing tip was sealed by squeezing it with a pair of pliers. The tip with the fluid was placed in the heated tip holder, shown as 98 in Figure 1. Using a second pipette, 60 μ L of antibody reagent was added to the sample, with the lower end of the Eppendorf pipette tip almost in contact with the sample, as shown as 3 in Figure 3. The Eppendorf tip must reach as far down as possible, without restricting the flow of the antibody reagent. Immediately after the antibody reagent is added, the absorbance spectrum was recorded as the zero-time measurement. Two minutes later, a second absorbance spectrum was recorded. This was

repeated for the 4 calibrators, and 5 independent samples used for validation of the developed calibration algorithm. The absorbance spectra for the calibrators and validation sample set are shown in Figures 4 and 5 respectively. The linear regression fit for the calibrators and validation sample set are shown in figures 6 and 7 respectively.

5 Similarly, calibration algorithms were developed β 2-microglobulin and C-reactive protein, and their linear regression fits are shown in Figures 8 and 9 respectively. The antibody used for β 2-microglobulin is covalently coupled to polystyrene beads in order to and the antibody used for CRP was unenhanced, like the IgA antibodies. These antibodies are also available commercially. It must be understood that any protein for
10 which specific antibodies are available, and where the concentration is sufficient to develop detectable immunocomplexes, can be measured by this invention. Furthermore, for proteins in relative low concentrations, the signals can be enhanced by coupling polystyrene beads to the antibody.

Due to the small absorbances which is expected at the wavelengths used, the
15 zero-time absorbance spectra obtained for IgA were observed to be in a random order, as shown in Figure 4, possible due to the presence of tiny air bubbles in the fluid and inconsistencies in the walls of the dispensing tip. However, after 2 minutes at 37°C, both the absorbances and the first derivative of the absorbance are proportional to the concentration of β 2-microglobulin, as shown in Figure 5. The prior art subtracts the zero
20 absorbance at around 340nm, from the absorbance at 340nm after the incubation at approximately 37°C for approximately 5 minutes, for the purpose of removing the effects of interferents in the sample. To those skilled in the art, the use of dispensing tips along with the prior art method to remove the effects of interferents cannot be use for the wavelength range as specified in this invention. The present invention uses a new
25 approach for removing the effects of interferents, where the first derivative of absorbance is subtracted from the first derivative of absorbance after 2 minutes at 37°C at every wavelength; the difference is then subjected to a statistical process of step-wise linear regression for the selection of optimal wavelengths. It will be understood that for the calculation of each first derivative of absorbance in the preferred embodiment, requires
30 the raw absorbances at 9 pixels or wavelengths; if filters were used instead of the PDA used in this invention, 2 narrow band-pass filters would be required to produce each first derivative of absorbance. Therefore, even if a single first derivative of absorbance is used in the calibration algorithm, multiple wavelengths are necessary.

In respect of IgA, optimal results may be obtained by calculating the first
35 derivative of absorbance at wavelengths of approximately 789nm and 825nm. In respect of β 2-microglobulin, optimal results may be obtained by calculating the first derivative of absorbance at wavelengths of approximately 548nm and 829nm. In respect of CRP, optimal results may be obtained by calculating the first derivative of absorbance at wavelengths

of approximately 661 nm and 679nm.

The calibration algorithm developed for IgA based on 4 calibrators is as follows;

$\text{mgIL IgA} = -3327114.33 (789\text{nm}) + 484270.80 (825\text{nm}) - 77.3$ where (Xnm) is the first derivative of the absorbance at the wavelength specified.

- 5 The calibration algorithm developed for $\beta 2$ -microglobulin based on 7 calibrators is as follows:

$\text{mg/L } \beta 2\text{-microglobulin} = -33648.79 (548\text{nm}) + 36556.81 (829\text{nm}) + 2.3$

where (Xnm) is the first derivative of the absorbance at the wavelength specified.

- 10 The calibration algorithm developed for CRP based on 9 calibrators is as follows:

$\text{mgL CRP} = -1813682.71 (661\text{nm}) + 1808677.58 (679\text{nm}) + 9.8$

where (Xnm) is the first derivative of the absorbance at the wavelength specified.

- 15 It will be understood that several calibration algorithms can be developed for each protein, using an apparatus described for measuring specimen integrity.


- The protein measurements are based on the principle of immunoturbidimetry, i.e., generation of antibody-antigen complexes or immunocomplexes which cause turbidity. The "absorbance" generated is due to light scattering caused by the immunocomplexes, therefore endogenous turbidity or true absorbances caused by interferents in the sample
20 will falsely elevate the signals. To demonstrate how interferents are dealt with, an aqueous solution of 2 g/L IgA was mixed with IL to provide 4 different samples with 1 g/L IgA and variable amounts of IL, i.e. from 0 to 4 g/L. Separate algorithms were developed for IgA with and without zero time correction.

- The error in the predicted results with and without zero time subtraction is shown
25 in Figure 10. This invention is different from the current art because multiple long wavelengths are used, and because of the small absorbances caused by the immunocomplexes at those wavelengths, endogenous interferents must be compensated for. This compensation cannot be performed using the raw absorbance due to the effect of small air bubbles and imprecise absorbance produce by disposable dispensing tips, but can be
30 performed effectively by using the 1st derivative of the absorbance. As long as the first derivative of absorbance is employed, multiple wavelengths are necessary, even if the calibration algorithm uses a single first derivative of absorbance.

- While the invention has been particularly shown and described with reference to preferred embodiments, it will be understood by those skilled in the art that various
35 other changes in form, and detail may be made without departing from the scope of the invention.


1/10

FIGURE 1



2/10

FIGURE 2



I CLAIM:

1. An apparatus for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry, said apparatus comprising:
 - a blood analyzer;
 - 5 a disposable dispensing tip;
 - means for sealing a first end of said disposable dispensing tip;
 - a second tip capable of being inserted into an open second end of said disposable dispensing tip for adding one or more reagents to said disposable dispensing tip;
 - a heated cavity for receiving said sample in said disposable dispensing tip of the
 - 10 analyzer;
 - means for transferring said disposable dispensing tip into and out of said heated cavity;
 - a radiation source for emitting a beam of radiation;
 - means for directing said radiation onto said sample in said disposable dispensing
 - 15 tip;
 - a sensor responsive to receipt of said radiation; and
 - means for correlating said concentration of said one or more proteins in said sample to a sensor response from said sample.
2. The apparatus of claim 1 wherein said means for sealing is a vice.
- 20 3. The apparatus of claim 1 or 2 wherein the radiation source means, means for directing said radiation onto said sample, and sensor are contained in a spectrophotometer.
4. The apparatus as claimed in claim 1-2 wherein said beam of radiation is near infrared and adjacent visible region light.
- 25 5. The apparatus as claimed in claims 1-4 wherein said near infrared and adjacent visible region light has wavelengths from about 475nm to about 910nm.
6. The apparatus as claimed in claims 1-5 wherein said means for correlation incorporates calibration algorithms in respect of IgA, β 2-microglobulin and C-reactive protein (CRP) respectively which are:
 - 30 a. $\text{mg/L IgA} = -a(X\text{nm}) + b(Y\text{nm}) - c$
where a, b and c are coefficients of the first derivative of absorbances at the

wavelengths X and Y; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 780-800 nm, and Y is about 820-830 nm;

b. $\text{mg/L } \beta 2\text{-microglobulin} = a(Xnm) + b(Ynm) + c$

5 where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 545-550 nm and Y is about 825-835 nm; and

c. $\text{mg/L CRP} = a(Xnm) + b(Ynm) + c$

10 where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 655-665 nm and Y is about 675-685 nm.

7. The apparatus as claimed in claim 6, wherein respect of the calibration algorithm
15 for IgA, $a = 3327100\text{-}3327120$, $b = 484250\text{-}484290$ and $c = 70\text{-}85$;
in respect of the algorithm for $\beta 2\text{-microglobulin}$, $a = -33640\text{-}33660$, $b = 36550\text{-}36560$ and $c = 2\text{-}3$; and
in respect of the algorithm for C-reactive protein $a = (-1813675)\text{-}(-1813685)$, $b = 1808670\text{-}1808680$ and $c = 9.5\text{-}10$.

20 8. The apparatus as claimed in claim 7, wherein calibration algorithms in respect of IgA, $\beta 2\text{-microglobulin}$ and C-reactive protein respectively are:

a. $\text{mg/L IgA} = -a(Xnm) + b(Ynm) - c$

25 where $a = 3327114.33$, $b = 484270.80$ and $c = 77.3$; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 789 nm and Y is about 825nm;

b. $\text{mg/L } \beta 2\text{-microglobulin} = a(Xnm) + b(Ynm) + c$

30 where $a = -33648.79$, $b = 36556.81$ and $c = 2.3$; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 548 nm and Y is about 829m; and

c. $\text{mg/L CRP} = a(X_{nm}) + b(Y_{nm}) + c$

where $a = -1813682.71$, $b = 1808677.58$ and $c = 9.8$ (X_{nm}) is the first derivative of the absorbance at wavelength X ; (Y_{nm}) is the first derivative of the absorbance at wavelength Y ; where X is about 661nm and Y is about 679nm.

5

9. A method for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry in a blood analyzer, said method comprising:

filling a disposable dispensing tip with the sample;

sealing a first end of the tip with means for sealing;

10 adding a reagent to an open second end of the disposable dispensing tip with a second tip capable of being inserted into said open end;

placing the disposable dispensing tip into a heated cavity;

radiating the sample in the disposable dispensing tip with a source which emits a beam of radiation;

15 sensing the radiation having passed through the sample; and

correlating the concentration of said one or more protein in said sample to the sensor response from the sample.

10. The method of claim 9 wherein said means for sealing is a vice.

11. The method as claimed in claim 9 or 10 wherein said beam of radiation is near
20 infrared and adjacent visible region light.

12. The method as claimed in any one of claims 9-11 wherein said near infrared and adjacent visible region light has wavelengths from about 475nm to about 910nm.

13. The method as claimed in any one of claims 9-12 wherein said means for correlation incorporates calibration algorithms in respect of IgA, β 2-microglobulin and C-reactive protein (CRP) respectively:
25

a. $\text{mg/L IgA} = -a(X_{nm}) + b(Y_{nm}) - c$

where a , b and c are coefficients of the first derivative of absorbances at the wavelengths X and Y ; (X_{nm}) is the first derivative of the absorbance at the wavelength specified; (Y_{nm}) is the first derivative of the absorbance at wavelengths Y ; where X
30 equals 780-800 nm, and Y equals 820-830 nm;

b. $\text{mg/L } \beta$ 2-microglobulin = $a(X_{nm}) + b(Y_{nm}) + c$

where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X and Y are 545-550 nm and 825-835 nm, respectively; and

5 c. $\text{mg/L CRP} = a(X_{nm}) + b(Y_{nm}) + c$

where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X and Y equal 655-665 nm; 675-685 nm, respectively.

- 10 14. The method as claimed in claim 13, wherein respect of the calibration algorithm for IgA, $a = 3327100-3327120$, $b = 484250-484290$ and $c = 70-85$;
in respect of the algorithm for $\beta 2$ -microglobulin, $a = -33640-33660$, $b = 36550-36560$ and $c = 2-3$; and
in respect of the algorithm for C-reactive protein $a = (-1813675)-(-1813685)$, $b = 1808670-$
15 1808680 and $c = 9.5-10$.

15. The method as claimed in claim 14, wherein calibration algorithms in respect of IgA, $\beta 2$ -microglobulin and C-reactive protein respectively are:

a. $\text{mg/L IgA} = -a(X_{nm}) + b(Y_{nm}) - c$

20 where $a = 3327114.33$, $b = 484270.80$ and $c = 77.3$; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 789 nm and Y is about 825nm;

b. $\text{mg/L } \beta 2\text{-microglobulin} = a(X_{nm}) + b(Y_{nm}) + c$

25 where $a = -33648.79$, $b = 36556.81$ and $c = 2.3$; (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 548 nm and Y is about 829m; and


c. $\text{mg/L CRP} = a(X_{nm}) + b(Y_{nm}) + c$

30 where $a = -1813682.71$, $b = 1808677.58$ and $c = 9.8$ (Xnm) is the first derivative of the absorbance at wavelength X; (Ynm) is the first derivative of the absorbance at wavelength Y; where X is about 661nm and Y is about 679nm.

16. A method for determining the concentration of plasma protein IgA, β 2-microglobulin or C-reactive protein in a plasma sample by immunoturbidimetry in a blood analyzer, said method comprising:
- aspirating a small volume of plasma into a disposable dispensing tip;
 - 5 - further aspirating the small sample in the sample tip to pull the sample away from the lower end of the tip;
 - sealing the lower end of the tip with means for sealing the tip without trapping air below the sample in the tip;
 - adding an antibody reagent to the disposable dispensing tip with a second
 - 10 dispensing tip, the second tip is capable of being inserted into the open end of the disposable dispensing tip;
 - heating the disposable dispensing tip in a heating cavity;
 - radiating the sample in the disposable dispensing tip with a
 - 15 spectrophotometer; and
 - correlating the concentration of the IgA, β 2-microglobulin or C-reactive protein in the sample to a sensor response from the sample.
17. A method of claim 16 wherein the temperature of the heating cavity is 37°C.
18. A method of claim 17 wherein the tip is maintained in a heating cavity for 2 minutes.
- 20 19. A method of claim 17 or 18 wherein the plasma sample is 5 μ l.
20. A method of any one of claims 16 to 19 wherein the antibody reagent is about 60 μ l of antibody selected from the group consisting of:
- antibody reactive to IgA;
 - antibody reactive to β 2-microglobulin; and
 - 25 antibody reactive to C-reactive protein.


3/10

FIGURE 3




4/10

FIGURE 4




5/10

FIGURE 5




6/10

FIGURE 6




7/10

FIGURE 7




8/10

FIGURE 8




9/10

FIGURE 9



10/10

FIGURE 10



INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00236

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 B01L3/02 G01N1/38 G01N21/82

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 403 745 A (OLLINGTON) 4 April 1995 see column 1, paragraph 1 see column 1, line 55 - line 58 see column 13, line 18 - column 14, line 5 see column 14, last paragraph - column 15, line 7 see figures 11-16	1,3,9,16
A	EP 0 670 483 A (FUJI PHOTO FILM) 6 September 1995 see abstract see page 5, line 14 - line 30 see page 6, paragraph 1 see figures 1A-1E	1,9,16
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 June 1999

Date of mailing of the international search report

01/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Thomas, R.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 339 277 A (MILES) 2 November 1989</p> <p>see column 1, line 12 - line 22 see column 17, line 29 - line 33 see column 18, line 51 - line 53 see column 24, line 23 - line 24</p>	1,9,16, 17
A	<p>US 5 376 313 A (KANEWSKE) 27 December 1994</p> <p>see column 14, line 3 - column 15, line 31 see column 18, line 53 - column 19, line 10 see column 31, line 7 - line 14</p>	1,9,16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00236

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5403745 A	04-04-1995	AU 659797 B	01-06-1995
		AU 7762491 A	27-11-1991
		CA 2081559 A	28-10-1991
		DE 69126664 D	31-07-1997
		DE 69126664 T	30-10-1997
		EP 0527212 A	17-02-1993
		WO 9117441 A	14-11-1991
		US 5783400 A	21-07-1998
EP 0670483 A	06-09-1995	JP 7239334 A	12-09-1995
		US 5555767 A	17-09-1996
EP 0339277 A	02-11-1989	US 4990075 A	05-02-1991
		AU 3256489 A	12-10-1989
		CA 1330197 A	14-06-1994
		JP 2022560 A	25-01-1990
		JP 2711354 B	10-02-1998
		US 5084397 A	28-01-1992
		US 5162237 A	10-11-1992
US 5376313 A	27-12-1994	AU 3934993 A	08-11-1993
		CA 2129246 A	14-10-1993
		EP 0637283 A	08-02-1995
		JP 7505343 T	15-06-1995
		WO 9319928 A	14-10-1993
		US 5646049 A	08-07-1997
		US 5635364 A	03-06-1997
		US 5605665 A	25-02-1997
		US 5575978 A	19-11-1996
		US 5627522 A	06-05-1997
		US 5536471 A	16-07-1996
		US 5507410 A	16-04-1996
		US 5540890 A	30-07-1996
		US 5610069 A	11-03-1997
		US 5578494 A	26-11-1996
		US 5762878 A	09-06-1998
		AU 3929093 A	08-11-1993
		AU 3934393 A	08-11-1993
		AU 3935093 A	08-11-1993
		AU 3967793 A	08-11-1993
		AU 3968093 A	08-11-1993
		CA 2129245 A	14-10-1993
		CA 2129367 A	14-10-1993
		CA 2129368 A	14-10-1993
		CA 2132959 A	14-10-1993
		CA 2132960 A	14-10-1993
		EP 0755519 A	29-01-1997
		EP 0634016 A	18-01-1995
		EP 0746769 A	11-12-1996
		EP 0632894 A	11-01-1995
		EP 0632896 A	11-01-1995
		JP 7505473 T	15-06-1995
		JP 7505474 T	15-06-1995
		JP 2769245 B	25-06-1998
		JP 7505475 T	15-06-1995
		JP 7505476 T	15-06-1995
		JP 7506184 T	06-07-1995
		WO 9320440 A	14-10-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00236

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5376313 A		WO 9320444 A	14-10-1993
		WO 9320443 A	14-10-1993
		WO 9320441 A	14-10-1993
		WO 9320450 A	14-10-1993
		US 5358691 A	25-10-1994
		US 5482861 A	09-01-1996
		US 5451528 A	19-09-1995